Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Cancer Cell · 2023-10 · 41 (10) · 1731-1748.e8
DOI: 10.1016/j.ccell.2023.09.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2023-10. Verfasst von Mingrui Zhu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Simmons Comprehensive Cancer Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Welch Foundation, Mary Kay Ash Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Simmons Comprehensive Cancer Center, Dallas, TX, USA.
- Quantitative Biomedical Research Center, Department of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Simmons Comprehensive Cancer Center, Dallas, TX, USA; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Simmons Comprehensive Cancer Center, Dallas, TX, USA; Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Pharmacology, University of Texas Southwestern Medical Ce…
- Simmons Comprehensive Cancer Center, Dallas, TX, USA; Department Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Förderung
- NCI NIH HHS
- Welch Foundation
- Mary Kay Ash Foundation
- National Institutes of Health
- AstraZeneca
- U.S. Department of Defense
- Cancer Prevention and Research Institute of Texas
- American Cancer Society
Zitieren
APA
Zhu, M., Kim, J., Deng, Q., Ricciuti, B., Alessi, J. V., Eglenen-Polat, B., Bender, M. E., Huang, H. C., Kowash, R. R., Cuevas, I., Bennett, Z. T., Gao, J., Minna, J. D., Castrillon, D. H., Awad, M. M., Xu, L., & Akbay, E. A. (2023). Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell, 41(10), 1731-1748.e8. https://doi.org/10.1016/j.ccell.2023.09.006
Vancouver
Zhu M, Kim J, Deng Q, Ricciuti B, Alessi JV, Eglenen-Polat B, et al. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell. 2023;41(10):1731-1748.e8. doi:10.1016/j.ccell.2023.09.006
BibTeX
@article{Zhu2023,
author = {Zhu, Mingrui and Kim, Jiwoong and Deng, Qing and Ricciuti, Biagio and Alessi, Joao V and Eglenen-Polat, Buse and Bender, Matthew E and Huang, Hai-Cheng and Kowash, Ryan R and Cuevas, Ileana and Bennett, Zachary T and Gao, Jinming and Minna, John D and Castrillon, Diego H and Awad, Mark M and Xu, Lin and Akbay, Esra A},
title = {Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {10},
pages = {1731--1748.e8},
doi = {10.1016/j.ccell.2023.09.006}
}
EUVIMED